Recombinant human TL1A/TNFSF15 protein - Bioactive cytokine

Recombinant cytokine, source: CHO cells

ABOUT

Human TL1A protein - Mammalian cell-expressed, tag-free, carrier-free

Recombinant human TL1A is a high-quality and biologically active cytokine, validated using proprietary TL1A reporter cells. This member of the TNF superfamily is produced in CHO cells to ensure protein glycosylation and bona fide 3D structure. Human TL1A produced in E. coli can form aggregates, potentially impairing its intracellular signaling efficiency (in-house observations).

Recombinant human TL1A can be used together with HEK-Blue™ TL1A cells for the screening of inhibitory molecules, such as Tulisokibart, a monoclonal antibody targeting TL1A (see figures).

 

Key features

  • Each lot is validated using HEK-Blue™ TL1A cells
  • Endotoxin ≤ 0.1 EU/µg
  • 0.2 µm sterile-filtered

Applications

  • Standard for TL1A detection and quantification
  • Screening and release assays for antibodies blocking TL1A signaling
  • Screening and release assays for engineered TL1A

 

Tumor necrosis factor (TNF)-like 1A (TL1A) drives the production of pro-inflammatory cytokines and differentiation of T helper subsets. Abnormal TL1A expression is linked to enteric autoimmune diseases (e.g. Crohn’s disease) and extends to other diseases including allergic airway inflammation.

More details

All InvivoGen products are for internal research use only, and not for human or veterinary use.

TL1A signaling and biological functions
TL1A signaling and biological functions

SPECIFICATIONS

Specifications

Source
CHO cells
Species
Human
Synonyms
TNFSF15
Accession sequence

O95150

Protein size
180 a.a. (L72-L251)
Molecular weight
~ 24-27 kDa (monomer) (SDS-PAGE)
Carrier
Carrier-free
Tag
Tag-free
Purity
≥ 95% (SDS-PAGE)
Solubility

100 μg/ml in water

Formulation buffer

Phosphate buffer saline (pH 7.4), 5% saccharose

Appearance (form)
Lyophilized
Reconstitution buffer
Endotoxin-free water (provided)
Sterility

0.2 µm filtration

Endotoxin

The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK‑Blue™ TLR4 cells.

Applications

Cellular assays (tested), ELISA

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Recombinant human TL1A
  • Cat code: 
    rcyc-htl1a
  • Quantity: 
    20 µg
Includes:

1.5 ml endotoxin-free water

Shipping & Storage

  • Shipping method:  Room temperature

    • Storage:

    • -20°C
    Stability: -20°C for up to 1 year

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

TL1A background

Tumor necrosis factor (TNF)-like 1A (TL1A), also called TNFSF15, is a cytokine that belongs to the TNF superfamily. TL1A is produced by endothelial cells, activated dendritic cells, and macrophages. It is synthesized as a membrane-bound trimeric molecule. Alternative splicing or cleavage by the tumor necrosis factor-alpha converting enzyme results in soluble TL1A [1]. Both forms bind the homotrimeric transmembrane death receptor 3 (DR3), triggering TRADD/TRAF2/RIP signaling, and ultimately leading to NF-κB and MAPKs activation. Subsequent gene expression in target cells drives the production of pro-inflammatory cytokines and differentiation of T helper subsets [1].

 

Relevance for therapeutics development

TL1A is normally responsible for mediating protective immune responses. However, it can also play a role in chronic inflammatory disorders and have harmful impacts. Abnormal TL1A expression or TL1A overactivity promotes excessive inflammation and immune cell infiltration, contributing to tissue damage and further inflammation amplification [1].

Pharmaceutical companies have developed potent monoclonal antibodies to block TL1A signaling and stop the downstream inflammatory cascade and tissue damage, primarily in the onset of asthma and Crohn’s disease. Anti-TL1A inhibitors such as Tulisokibart (MK-7240 or PRA023, Merck), RVT-3101 (PF-06480605, Roche), and Duvakitug (TEV-48574, Sanofi & Teva Pharmaceuticals) have demonstrated "best-in-class" potential for treating inflammation and scarring in IBD [2-4]. Duvakitug is currently being studied for its safety as an asthma medication [5-6].

 

References:

1. Xu W.D., et al., 2022. Role of TL1A in Inflammatory Autoimmune Diseases: A Comprehensive Review. Front. Immunol. 13: 891328.
2. Sands, B.E., et al., 2024. Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis. N Engl J Med, 391(12): p. 1119-1129.
3. Danese, S., et al., 2021. Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study. Clinical Gastroenterology and Hepatology. 19(11): p. 2324-2332.e6.
4. Solitano, V., et al., 2024. TL1A inhibition for inflammatory bowel disease treatment: From inflammation to fibrosis. Med. 5(5): p. 386-400.
5. Balyan, R., et al.,, 2024. P633 First-in-Human Pharmacokinetic and Safety Study of an Anti-TL1A Antibody, TEV-48574, in Healthy Volunteers and Asthma Patients. Journal of Crohn's and Colitis. 18(Supplement_1): p. i1215-i1216.
6. Raphael, G., et al., 2024. P1061 TEV-48574, an anti-TL1A antibody in development for use in IBD, is safe and well tolerated following 16 weeks of subcutaneous treatment in adults with severe uncontrolled T2-low/non T2 asthma. Journal of Crohn's and Colitis. 18(Supplement_1): p. i1908-i1908.

You may also need

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?